Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525649 · ClinicalTrials.gov registry record · Phase 1
A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
A Phase 1 study, sponsored by NeuroPro Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06525649: Completed Phase 1 study, sponsored by NeuroPro Therapeutics.
NCT06525649 is a Phase 1 study that has completed, run by NeuroPro Therapeutics. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06525649, a Phase 1 study, has completed, sponsored by NeuroPro Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.
Primary Outcome
Evaluate the change in the adjudicated SPR (standard photosensitivity range) in subjects receiving each different dose strengths of NPT 2042 compared to placebo in the most sensitive eye condition. The most sensitive eye condition will be determined at the screening visit.
Interventions
- DRUG NPT 2042
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-06-26 |
| Phase | Phase 1 |
What the finished NCT06525649 record still lists
NCT06525649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which NPT 2042 is the first listed.
NCT06525649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06525649 about?
NCT06525649 is a clinical study titled "A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042". A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.
What is the current status of trial NCT06525649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-08-21. Estimated completion is 2025-06-26.
What interventions are being tested in trial NCT06525649?
The interventions under investigation include: NPT 2042 (DRUG).
Who is sponsoring clinical trial NCT06525649?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06525649's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI